Merck (MRK) And Ridgeback Announce Publication of Phase 3 Study of Molnupiravir
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Buildings collapse as quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Daiwa Securities Starts Merck (MRK) at Neutral (3)
December 16, 2021 4:25 AM ESTDaiwa Securities initiates coverage on Merck (NYSE: MRK) with a Neutral (3) rating and a price target of $70.00.
For an analyst ratings summary and ratings history on Merck click here. For more ratings news on Merck click here.
Shares of Merck closed at $75.29 yesterday.
... MoreMerck's (MRK) VAXNEUVANCE Approved in the EU for Individuals 18 Years of Age and Older
December 15, 2021 6:45 AM ESTMerck (NYSE: MRK), known as MSD outside the United States and Canada, announced today the European Commission (EC) has approved VAXNEUVANCE (Pneumococcal 15-valent Conjugate Vaccine) for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older. The approval allows marketing of VAXNEUVANCE in all 27 European Union (EU) Member States plus Iceland, Norway and Lichtenstein. The use of VAXNEUVANCE in the EU should be in accordance with official recommendations.
The ECs decision follows a positive opinion from the European Medicines Agencys... More
